

参考文献

P.76～

New Products

タラゾパリブとエンザルタミドの併用療法

- 01 Prescrire team. Talazoparib (Talzenna®)+enzalutamide in metastatic prostate cancer resistant to androgen deprivation therapy. *Prescrire International* 2025;34(270):125-126
- 02 El-Taji O, Taktak S, Jones C et al. Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer: A Systematic Review and Meta-Analysis. *JAMA Oncol* 2024;10:874-884 doi: 10.1001/jamaoncol.2024.1549. PMID: 38842801
- 03 Beer TM, Armstrong AJ, Rathkopf DE et al. Enzalutamide in metastatic prostate cancer before chemotherapy. *NEJM* 2014;371:424-433, doi: 10.1056/NEJMoa1405095. Epub 2014 Jun 1. PMID: 24881730
- 04 Asim M, Tarish F, Zecchini HI Synthetic lethality between androgen receptor signalling and the PARP pathway in prostate cancer. *Nat Commun.* 2017 Aug 29;8(1):374. doi: 10.1038/s41467-017-00393-y. PMID: 28851861
- 05 Maiorano BA, Catalano M, Mercinelli C, Cigliola A et al. Incidence and Risk of Thromboembolic and Cardiovascular Adverse Events with PARP Inhibitor Treatment in Patients with Metastatic Castration-resistant Prostate Cancer: A Systematic Review and Safety Meta-analysis. *Eur Urol Open Sci.* 2025 Jan 10;72:1-9. doi: 10.1016/j.euros.2024.12.008. eCollection 2025 Feb. PMID: 39882554
- 06 Fizazi K, Azad AA, Matsubara N et al. First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial. *Nat Med.* 2024 Jan;30(1):257-264. doi: 10.1038/s41591-023-02704-x. Epub 2023 Dec 4. PMID: 38049622
- 07 Heiss BL, Chang E, Gao X et al. US Food and Drug Administration Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment of Patients With Homologous Recombination Repair Gene-Mutated Metastatic Castration-Resistant Prostate Cancer. *J Clin Oncol.* 2024 May 20;42(15):1851-1860. doi: 10.1200/JCO.23.02182. Epub 2024 Mar 7. PMID: 38452327
- 08 ターゼナ・インタビューフォーム
- 09 Agarwal N Final TALAPRO-2 Results: First-Line Talazoparib Plus Enzalutamide Improves Survival in Unselected Patients With mCRPC. *ASCO Daily news* Feb 13, 2025 <https://dailynews.ascopubs.org/do/final-talapro-2-results-first-line-talazoparib-plus-enzalutamide-improves-survival>
- 10 Matsubara N, Miyake H, Uemura H, Phase 3 Study of Talazoparib Plus Enzalutamide Versus Placebo Plus Enzalutamide as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer: TALAPRO-2 Japanese Subgroup Analysis. *Cancer Med.* 2025 Jan;14(1):e70333. doi: 10.1002/cam4.70333. PMID: 39737542